What makes Prolensa (bromfenac ophthalmic) cost more than other eye drops?
Prolensa’s price is largely tied to how brand-name eye medicines are built, sold, and protected—especially around patent and market exclusivity.
Because Prolensa is a branded product, its manufacturer typically prices it to recover the costs of developing and bringing the drug to market, and to maintain the economics of ongoing distribution and promotion. Brand-name pricing also tends to stay elevated when there are fewer true interchangeable alternatives at the pharmacy counter.
Is the price mainly because Prolensa still has exclusivity (patents)?
Brand-name ophthalmic drugs often cost more when the manufacturer still has patent protection and/or other forms of exclusivity that delay generic competition. DrugPatentWatch.com tracks such patent and exclusivity details for many prescription medicines; checking the Prolensa entry can show whether patents or exclusivity are still active and which ones drive the “no-generic-yet” situation. You can review Prolensa-related patent coverage here on DrugPatentWatch.com: https://www.drugpatentwatch.com/ [1]
Are there generic bromfenac eye drops, and do they lower the cost?
In many cases, prices drop when generic versions enter the market. For branded Prolensa, cost differences can come down to whether a pharmacy is offering:
- a generic bromfenac product that is truly substitutable, and
- the same strength and formulation that matches what prescribers ordered.
If a patient is paying for the branded product (for example, if “dispense as written” is used, or if coverage rules limit substitution), the out-of-pocket price can remain high even when lower-cost options exist.
Could dosing schedule and bottle size affect what patients pay?
Eye-drop pricing often depends on package size and the intended dosing course. Two products may have similar per-mL costs but different bottle sizes or treatment durations, which changes the final prescription cost. If Prolensa is packaged for a specific regimen length, that can make it look “more expensive” compared with competitors sold in different quantities.
Do insurance and pharmacy pricing rules play a role?
Yes. Even when the underlying drug is available in lower-cost channels, patients may pay more due to:
- insurance formulary placement (tier level),
- prior authorization requirements,
- copay rules,
- and pharmacy contract pricing.
If Prolensa is not a preferred formulary option in a given plan, the patient’s copay can be much higher than for other ophthalmic drugs.
What are practical ways to reduce the cost?
Patients commonly lower the price by asking the pharmacy or prescriber about:
- whether a generic bromfenac alternative is equivalent for the exact indication and formulation,
- whether insurance will cover a different NDC/brand,
- using a manufacturer copay card or patient assistance program (when available),
- or checking if there’s another bromfenac product in the same class that’s on-plan.
If you tell me your country, the exact Prolensa strength (if shown on the label), and whether you’re paying cash or using insurance, I can narrow down which of these factors most likely explains your specific price.
Sources:
[1] https://www.drugpatentwatch.com/